CymaBay Therapeutics (CBAY) Stock Price, News & Analysis

Company Overview

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

Key Stats

• Today's Range: $32.48 to $32.48
• 50-Day Range: $32.18 to $32.48
• 52-Week Range: $7.26 to $32.50
• Volume: 73 shs
• Average Volume: 4.11 million shs
• Market Capitalization: $3.73 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.50
• Consensus Rating: Hold

CymaBay Therapeutics Stock Analysis - MarketRank™

CymaBay Therapeutics scored higher than 16% of companies evaluated by MarketBeat, and ranked 878th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

CymaBay Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 11 hold ratings, and no sell ratings.

Amount of Analyst Coverage

CymaBay Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CymaBay Therapeutics are expected to grow in the coming year, from ($1.38) to ($1.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CymaBay Therapeutics is -33.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CymaBay Therapeutics is -33.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CymaBay Therapeutics has a P/B Ratio of 12.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CBAY.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CymaBay Therapeutics does not currently pay a dividend.

Dividend Growth

CymaBay Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.88

Short Interest

There is no current short interest data available for CBAY.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CymaBay Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.00% of the stock of CymaBay Therapeutics is held by insiders.

Percentage Held by Institutions

95.03% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CBAY Stock Analysis - Frequently Asked Questions

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) posted its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.04. The biopharmaceutical company earned $0.06 million during the quarter, compared to analyst estimates of $0.42 million.

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CymaBay Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 2/28/2024
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CBAY
• CUSIP: N/A
• CIK: 1042074
• Web: www.cymabay.com
• Phone: (510) 293-8800
• Fax: 510-293-9090
• Employees: 101
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $32.50
• High Stock Price Target: $32.50
• Low Stock Price Target: $32.50
• Potential Upside/Downside: +0.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 11 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-105,370,000.00
• Net Margins: N/A
• Pretax Margin: -339.11%
• Return on Equity: -50.72%
• Return on Assets: -31.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.96
• Quick Ratio: 10.96

Sales & Book Value

• Annual Sales: $31.07 million
• Price / Sales: 119.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.58 per share
• Price / Book: 12.59

Miscellaneous

• Outstanding Shares: 114,724,000
• Free Float: 106,693,000
• Market Cap: $3.73 billion
• Optionable: Optionable
• Beta: 0.32